Altimmune Inc.’s ability to start clinical trials for its coronavirus vaccine candidate now lies in the hands of regulators.
The Gaithersburg biotech has submitted its investigational new drug application for its intranasal Covid-19 vaccine, AdCovid, to the Food and Drug Administration, the company said Wednesday. An approval would allow the company to initiate a phase 1 study of the candidate.
Altimmune (NASDAQ: ALT) is on track to kick off that trial in 2020 and report data in the first quarter of 2021, said President and CEO Vipin Garg in a statement. Based on that data, the company “would plan to move swiftly” into a phase 2 clinical trial next year, he told us previously.
Read the full article at: www.bizjournals.com
The following two tabs change content below.
Chris Frew
President, CEO at Biobuzz Media & Workforce Genetics
Over the past 8 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.
Latest posts by Chris Frew (see all)
- Dr. Anthony Fauci & AGT’s Jeff Galvin Join ‘I AM BIO’ to Discuss Future of HIV Treatments - September 14, 2021
- Data Center Firm DataBridge Sites Expands into Philadelphia, Maryland, and Chicago | Business Wire - September 7, 2021
- VaLogic acquires vacant Frederick building to create tech hub - August 31, 2021
- New Frederick facility delivers in-demand lab, workspace for growing biotech firms - August 27, 2021
- Intralytix Receives Fast Track NIH SBIR Contract to Develop a Universal, Scale-independent AI-based Platform for Manufacturing High Titer Bacteriophage Preparations for Clinical Applications - August 18, 2021
